Therefore, we hypothesized that two major nuclear NAD+-dependent mechanisms underlie the tumor-promoting role of NMNAT1 in ActD-treated osteosarcoma cells: PARP and SIRT activities. The gene discussed is PARP1; the disease is osteosarcoma.